Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cell Procurement

Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

Bone Marrow Transplantation volume 39, pages 743–750 (2007)Cite this article

Abstract

High-dose chemotherapy followed by autologous blood stem cell transplantation is the standard treatment for myeloma patients. In this study, CAD (cyclophosphamide, adriamycin, dexamethasone) chemotherapy and a single dose of pegfilgrastim (12 mg) was highly effective in mobilizing peripheral blood stem cells (PBSCs) for subsequent transplantation, with 88% of patients (n=26) achieving the CD34+ cell harvest target of ⩾7.50 × 106 CD34+ cells/kg body weight, following a median of two apheresis procedures (range 1–4) and with first apheresis performed at a median day 13 after CAD application (range 10–20). Patients treated with pegfilgrastim showed a reduced time to first apheresis procedure from mobilization compared with filgrastim-mobilized historical matched controls (n=52, P=0.015). The pegfilgrastim mobilization regimen allowed for transplantation of a median of 3.58 × 106 CD34+ cells/kg body weight while leaving sufficient stored cells for a second high-dose regimen and back-ups in most patients. Engraftment following transplantation was comparable to filgrastim, with a median time of 14 days to leucocyte ⩾1.0 × 109/l (range 10–21) and 11 days to platelets ⩾20 × 109/l (range 0–15). The results of this study thus provide further support for the clinical utility of pegfilgrastim for the mobilization of PBSC following chemotherapy in cancer patients scheduled for transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Harousseau JL, Moreau P . Evolving role of stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma 2005; 6: 89–95 (Review).

    Article  Google Scholar 

  2. Watts MJ, Ings SJ, Leverett D, MacMillan A, Devereux S, Goldstone AH et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(−2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278–282.

    Article  CAS  Google Scholar 

  3. Zamboni WC . Pharmacokinetics of pegfilgrastim. Pharmacotherapy 2003; 23: 9S–14S.

    Article  CAS  Google Scholar 

  4. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727–731.

    Article  CAS  Google Scholar 

  5. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al. International Pegfilgrastim 749 Study Group. A randomized, double-blind, multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29–35.

    Article  CAS  Google Scholar 

  6. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ . A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II–IV breast cancer. Oncol Rep 2003; 10: 715–724.

    CAS  PubMed  Google Scholar 

  7. Wolf T, Densmore JL . Pegfilgrastim use during chemotherapy: current and future applications. Curr Hematol Rep 2004; 3: 419–423.

    PubMed  Google Scholar 

  8. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Rosa Motta M et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225–231.

    CAS  PubMed  Google Scholar 

  9. Russell N, Mesters R, Pfreundschuh M, Boogaerts M, Johnsen H, del Canizo M et al. Pegfilgrastim (6 mg or 12 mg) mobilises CD34+ cells similarly to filgrastim (5 μg/kg/day) when administered following chemotherapy in patients with non-Hodgkin's lymphoma. Blood 2005; 106: 560a (Abstract 1977).

    Google Scholar 

  10. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilised by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33–36.

    Article  CAS  Google Scholar 

  11. Noga SJ, Oroszlan M, Zhang YL, Kassa MB, Hetherington J, Feldman MJ et al. Single dose pegfilgrastim successfully mobilises optimal numbers of autologous CD34+ cells for peripheral blood stem cell collection. Blood 2002; 100: 826a, Abstract 3262.

    Google Scholar 

  12. Noga S, Oroszlan M, Hetherington J . Use of pegfilgrastim for autologous peripheral blood stem cell mobilisation: comparison to a daily filgrastim regimen. Bone Marrow Transplant 2003; 31: S18.

    Google Scholar 

  13. Kroschinsky F, Holig K, Platzbecker U, Haack A, Schaich M, Bornhauser M . Pegfilgrastim is able to mobilize autologous CD34+ peripheral blood progenitor cells in patients with lymphoid malignancies and solid tumors. Bone Marrow Transplant 2004; 33: S79 (Abstract P408).

    Article  Google Scholar 

  14. Mandanas RA, Underwood BJ, Geister BV, Smith JW . Pegfilgrastim (Neulasta) following chemotherapy leads to successful mobilisation of hematopoietic progenitor cells among transplant patients with various diagnoses. Biol Blood Marrow Transplant 2004; 10: 14 (Abstract 21).

    Article  Google Scholar 

  15. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U et al. Fixed dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 2006; 133: 533–537.

    Article  CAS  Google Scholar 

  16. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I . The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213–226.

    Article  CAS  Google Scholar 

  17. Bauer DF . Constructing confidence sets using rank statistics. J Am Stat Assoc 1972; 67: 687–690.

    Article  Google Scholar 

  18. Haas R, Witt B, Mohle R, Goldschmidt H, Hohaus S, Fruehauf S et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754–3761.

    CAS  PubMed  Google Scholar 

  19. Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006; 34: 1296–1302.

    Article  CAS  Google Scholar 

  20. Kroschinsky F, Hoelig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilisation of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46: 1417–1423.

    Article  CAS  Google Scholar 

  21. Morris ES, MacDonald KP, Hill GR . Stem cell mobilisation with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood 2006; 107: 3430–3435.

    Article  CAS  Google Scholar 

  22. Seggewiss R, Buss E, Herrmann D, Goldschmidt H, Ho AD, Fruehauf S . Kinetics of peripheral blood stem cell mobilisation following G-CSF-supported chemotherapy. Stem Cells 2003; 21: 568–574.

    Article  CAS  Google Scholar 

  23. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP et al. A single dose of 6 to 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilisation results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180–185.

    Article  CAS  Google Scholar 

  24. Goertz A, Dubois RW, Doan QV, Liu Z, Heissel A, von Minckwitz G . Primary prophylaxis against febrile neutropenia with pegfilgrastim is more cost effective than filgrastim in women with breast cancer receiving chemotherapy in Germany. ISPOR 9th Annual European Congress 2006, Copenhagen, Denmark; Abstract: PIN6.

Download references

Author information

Authors and Affiliations

  1. Department of Tumor Diagnostics and Therapy, Paracelsus Hospital, Osnabrueck, Germany

    S Fruehauf

  2. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

    S Fruehauf, J Klaus, E C Buss, J Topaly, T Seeger, T Moehler, A D Ho & H Goldschmidt

  3. Coordination Centre for Clinical Trials, Heidelberg, Germany

    J Huesing

  4. Department G402, Pharmacology of Cancer Treatment, German Cancer Research Center, Heidelberg, Germany

    M R Veldwijk, T Seeger & L W J Zeller

  5. Department of Radiation Oncology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany

    M R Veldwijk

Authors
  1. S Fruehauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Klaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Huesing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M R Veldwijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E C Buss
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Topaly
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Seeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L W J Zeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Moehler
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A D Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Fruehauf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fruehauf, S., Klaus, J., Huesing, J. et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 39, 743–750 (2007). https://doi.org/10.1038/sj.bmt.1705675

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705675

Keywords

This article is cited by

Search

Advanced search

Quick links